This study aimed to define the maximum-tolerated dose (MTD) of fixed dose rate (FDR) of gemcitabine (2 0 -2 0 -difluorodeoxycitidine) infusion with circulating haemopoietic progenitor support and to evaluate the activity of the treatment. Secondary end points were pharmacokinetic of gemcitabine and difluorodeoxyuridina (dFdU) measured at first course and the activity andexpression profile of cytidine deaminase (CdA) on circulating mononuclear cells. Patients with advanced pancreatic carcinoma received escalating dose of gemcitabine 10 mg m À2 min À1 every 2 weeks with circulating haemopoietic progenitor support. First dose level was 3000 mg m
Pancreatic carcinoma is the fifth most common cause of cancer death in Western countries. At diagnosis, the majority of patients have locally advanced unresectable or metastatic disease for which there is no curative therapy (Evans et al, 1997 (Evans et al, , p 1054 . For many years, 5-fluorouracil has been considered the standard treatment of pancreatic cancer with response rates ranging from 0 to 19% (Palmer et al, 1994) . More recently, gemcitabine (2 0 -2 0 -difluorodeoxycitidine) has proven activity against a variety of solid tumours including pancreatic cancer (Huang et al, 1991; Rothenberg et al, 1996) . A weekly short time (30 min) intravenous (i.v.) infusion of 1000 mg m À2 is the recommended dose and schedule. However, even if effective, this schedule might not to be the optimal one taking into account the metabolism of the drug.
Gemcitabine is a prodrug that is initially phosphorylated by deoxycytidine kinase (dCK) to gemcitabine monophosphate and subsequently to gemcitabine diphosphate and gemcitabine triphosphate. Incorporation of gemcitabine triphosphate into DNA inhibits replication with induction of apoptosis. Phosphorylation of gemcitabine to the monophosphate by deoxycytidine kinase is the rate-limiting step in the accumulation of the active diphosphate and triphosphate metabolites. Grunewald et al and Abbruzzese et al have demonstrated that the ability of mononuclear cells to accumulate gemcitabine triphosphate during therapy was saturable and the optimal plasma concentration of gemcitabine that maximised the rate of formation of gemcitabine triphosphate was approximately 20 mmol l À1 (Grunewald et al, 1990 (Grunewald et al, , 1991 . In these studies, this target plasma gemcitabine concentration and the optimal intracellular accumulation of gemcitabine triphosphate was achieved with dose rates of 10 mg m À2 min À1 (Abruzzese et al, 1991; Grunewald et al, 1992) . Based on these data, a number of phase I trials have explored the possibility to prolong the duration of infusion time; other trials escalated both the dose and infusion duration using a fixed dose rate (FDR) of 10 mg m À2 min À1 (Abbruzzese et al, 1991; Grunewald et al, 1992; Poplin et al, 1992; Pollera et al, 1997) . Tempero et al have compared in a phase II randomised trial the standard gemcitabine infusion in 30 min infusion vs an FDR infusion of 10 mg m À2 min À1 in pancreatic carcinoma. A significant increase in response rate, a longer median survival and a higher 1-year survival rate was reported in the FDR infusion-treated patients. However, patients receiving the FDR infusion experienced consistently more haematologic toxicity and cumulative myelosuppression was reported (Tempero et al, 2003) .
On the basis of these data from this trial and preclinical data suggesting a dose -response relationship (Csoka et al, 1995; Von Hoff, 1996) , we have designed a dose-finding phase I trial of gemcitabine given as prolonged FDR (10 mg m À2 min À1 ) infusion every 14 days with haemopoietic progenitor support in patients with advanced pancreatic adenocarcinoma.
End points of the study were to define the maximum-tolerated dose (MTD) of prolonged FDR of gemcitabine plus progenitor blood cells and to evaluate the activity of the treatment in terms of objective responses. Additive end points of the trial were to study the plasma pharmacokinetic of gemcitabine and its metabolite difluorodeoxyuridina (dFdU) following FDR infusion and to evaluate the influence of gene expression and activity of cytidine deaminase (CdA) on clinical outcome.
MATERIALS AND METHODS

Eligibility
Patients p75 years old, performance status 0 -1 (ECOG scale) with histologically confirmed unresectable advanced or metastatic pancreatic carcinoma were eligible for the study. Other eligibility criteria were bidimensionally measurable disease, leucocyte count X3.5 Â 10 9 l À1 , platelet count X100 Â 10 3 l À1 , haemoglobin level X10 g l À1 , no active infection, no severe concurrent medical condition and no previous treatment for the advanced disease. Prior adjuvant chemotherapy and/or radiotherapy was permitted. The patients were required to sign an informed consent and the Ethics Committee of St Chiara University Hospital approved the study.
Treatment plan
Granulocyte-colony-stimulating factor (G-CSF) 10 mg kg À1 day À1 subcutaneously (s.c.) was administered for 5 days to mobilise circulating haemopoietic progenitor cells. When the peripheral blood absolute CD34 þ cell count was X50 ml À1 , the aphaeresis procedure was performed using a Fenwall CS 3000 cell separator (Baxter, Chicago, IL, USA). Whole blood (8 -10 l) was processed per procedure using continuous flow blood at a flow rate of 50 ml min À1 . A minimum of 12 Â 10 6 CD34 þ cell kg À1 were collected from each patient.
Gemcitabine was administered at an FDR of 10 mg m À2 min À1 at the starting dose of 3000 mg m À2 (starting time infusion 300 min). If no dose-limiting toxicity occurred in the first two courses, the dose of gemcitabine was escalated by 500 mg m À2 in cohorts of three patients until maximum tolerable dose. In the absence of toxicity or progression, the courses were repeated every 14 days for a maximum of 12 courses. Peripheral blood progenitors were reinfused 24 h after each course of chemotherapy. At the time of reinfusion, frozen PBPC were thawed rapidly in a 371C warm bath and reinfused through a central venous catheter: at least 0.5 Â 10 6 CD34 þ cell kg À1 were reinfused per course. Following PBPC infusion, G-CSF 5 mg kg À1 day À 1 s.c. was administered starting day þ 5 to day þ 7.
Safety and activity assessment
A complete restaging of disease was performed after four, eight and 12 courses of treatment. Definition of response and toxicity were based on WHO criteria. Dose-limiting toxicity of gemcitabine was defined by one of the following criteria: G3 stomatitis lasting more than 5 days, G4 stomatitis and impossibility to recycle on day 14 in more than 40% of the courses. The MTD of gemcitabine was considered the dose level immediately below that producing one DLT out of three patients.
Pharmacokinetic analysis
Blood samples (4 ml each) were drawn at the first cycle of gemcitabine administration from an i.v. cannula placed in an antecubital vein before drug administration, after 30 min and every 3 h during infusion and 5, 15, 30, 45 min and 1, 3, 9, 15 and 24 h after the end of treatment and collected in heparinised test tubes containing 10 mM tetrahydrouridine (Calbiochem, San Diego, CA, USA) to inhibit gemcitabine metabolism by CdA. Plasma was obtained by centrifugation at 5000 g for 10 min, split in aliquots and stored at À801C.
Plasma levels of gemcitabine and its metabolite 2 0 , 2 0 -difluorodeoxyuridine (dFdU) were determined by a previously described reverse-phase high-performance liquid chromatography with ultraviolet detection (HPLC-UV) method optimised for the present study (Wang et al, 2003) . Drug extraction was performed by adding 80 ml of buffer (0.1 mol l À1 Tris-HCl, 50 mmol l À1 bmercaptoethanol, pH 8.0) and 50 ml of 40% (w v À1 ) trichloroacetic acid (TCA) to 120 ml of plasma. Samples were kept on ice for 20 min and proteins were precipitated by centrifugation for 10 min at 10 000 g. Supernatants were neutralised with 500 ml trioctylamine : 1,1,2-trichloro-trifluoroethane (1 : 4), centrifuged for 1 min at 10 000 g and 50 ml were injected onto a Simmetry Shield C 18 5 mm, 300 Â 4.6 mm column (Waters, Milford, MA, USA) eluted at a flow rate of 1 ml min À1 with 9% methanol, 6% acetonitrile and heptane sulphonic acid 5 mM, pH 3.1. The chromatographic apparatus was a Waters LC Module I plus equipped with a WISP 416 autosampler and a variable wavelength UV detector (Waters) set at 270 nm for peak detection. Calculation of gemcitabine and dFdU concentration in samples was performed against calibration curves in the range of 0.3 -300 mmol l À1 in the plasma of healthy donors. Maximum plasma concentration (C max , mmol l À1 ) of gemcitabine and dFdU were determined from visual inspection of the plasma concentration -time curves, while the area under the plasma concentration -time curve (AUC, min Â mmol l À1 ) was calculated with the linear trapezoidal rule.
Pharmacogenomic analysis
Analysis of CdA enzyme activity Mononuclear cells were obtained by density-gradient centrifugation of patients' blood samples (14 ml), obtained before drug administration, on FicollHypaque (density 1.077 g l
À1
, Pharmacia, Uppsala, Sweden). Cells were resuspended at 3 Â 10 6 cells 100 ml À1 of buffer (0.1 mol l
Tris-HCl, 50 mmol l À1 b-mercaptoethanol, pH 8.0 (van Haperen et al, 1996) . The suspension was sonicated and centrifuged for 20 min at 10 000 g to obtain crude cytoplasmatic extracts and 10 ml of 0.5 mmol l À1 gemcitabine was added to 50 ml of supernatant and 40 ml of buffer. Reaction mixture was incubated for 30 min at 371C and extraction of analytes was obtained with 25 ml 40% TCA. Samples were kept on ice for 20 min, neutralised with 250 ml tryoctylamine : 1,1,2-trichloro-trifluoroethane (1 : 4) and centrifuged for 5 min at 10 000 g. The upper layer was removed and analytes were separated by HPLC, as described above in 'Pharamacokinetic analysis'. Human mononuclear cells from blood donors were the source of cytoplasmatic extracts to be used as a calibrate matrix and spiked with dFdU to generate calibration curves, in the range of 33 -1000 mmol l À1 . The HPLC method was linear (R 2 40.995) for plasma and cytoplasmatic extracts over the analytical range and the limit of quantitation corresponded to the lower limit of the calibration curves. Intraday variability was 4À2.5 and o12% over the full analytical range of calibration standards, while interday variability was 4À1.5 and o15%. Concentrations of dFdU were normalised for cytoplasm protein concentration, which was measured with the Lowry reagent (Sigma, St Louis, MO, USA).
PCR analysis of CdA gene expression Total RNA was extracted using the TRI REAGENT LS (Sigma, St Louis, MO, USA) and dissolved in RNAse-free water containing 10 mmol l À1 dithiothreitol and 200 U ml À1 RNase inhibitor (Gibco, Gaithersburg, MD, USA). RNA (1 mg) was reverse transcribed at 371C for 1 h in 100-ml reaction volume containing 0.8 mM dNTPs (Sigma, St Louis, MO, USA), 200 U of MMLV-RT (Gibco, Gaithersburg, MD, USA), 40 U of RNase inhibitor and 0.05 mg ml À1 of random primers. The cDNA was amplified by quantitative, real-time PCR with the Applied Biosystems 7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA). PCR reactions were performed in triplicate using 5 ml of cDNA, 12.5 ml of TaqMan Universal PCR Master Mix (Applied Biosystems), 2.5 ml of probe and 2.5 ml of forward and reverse primers in a final volume of 25 ml. Forward (F) and reverse (R) primers and probe (P) were designed with Primer Express 2.0 (Applied Biosystems) on the basis of CdA gene sequence: 5 0 -TCAAAGGGTGCAACATAGAAAATG-3 0 (F), 5 0 -CGG TCCGTTCAGCACAGAT-3 0 (R) and 5 0 -CTGCTACCCGCTGGG-3 0 (P) (Demontis et al, 1998) . PCR thermal cycling conditions and optimisation of primer concentrations were reported in detail by Giovannetti et al (2004) . The amount of target gene, normalised to GAPDH and relative to the calibrator (mononuclear cells from volunteer blood donors), is given as 2 ÀDDCT .
Statistics
Data were expressed as mean values7s.d. and the Pearson/ Spearman correlation test and regression analysis were used to demonstrate the relationship between CdA expression, enzyme activity and dFdU AUC. Correlation between response rate and CdA expression and activity level was performed using w 2 test. Overall survival (OS) curves were calculated from the date of diagnosis until the date of death or last follow-up examination according to the Kaplan -Meier method and compared by the logrank test. Variables studied in univariate analysis included CdA expression and activity levels, dFdU AUC, age, sex and drug dose levels. Differences were considered significant if the Po0.05.
RESULTS
Characteristics of the patients
In all, 25 patients with locally advanced or metastatic pancreatic carcinoma entered into this the study. Two patients were unable to receive the planned treatment due to poor mobilisation of peripheral blood progenitors. A total of 23 patients collected the minimum number of CD34 þ cells to support at least one course of treatment. The median age was 56 years (range 42 -75 years) and median performance status (WHO scale) was 0 (range 0 -1). Three patients had locally advanced disease, 20 had metastatic disease: two patients had received previous adjuvant chemotherapy with gemcitabine as single agent. Predominant metastatic site was the liver in 14 patients (60.9%) ( Table 1 ). The median number of aphaeresis procedure per patients was 3 (range 2 -7) and median number of CD34 þ cell kg À1 collected per aphaeresis was 2.23 Â 10 6 (range 0.15 -10.1). Owing to the poor collection after G-CSF only, 15 patients underwent a further mobilisation with gemcitabine þ G-CSF. The average of CD34 þ cell kg À1 collected per aphaeresis after G-CSF and after gemcitabine þ G-CSF was 2.18 Â 10 6 (s.d.71.65 Â 10 6 ) and 4.12 Â 10 6 (s.d.72.46 Â 10 6 ), respectively. The difference was statistically significant (P ¼ 0.0001).
Toxicity
Three patients were treated for each dose level from 1st (3000 mg m À2 in 300 min) to 6th (6000 mg m À2 in 600 min), four patients at 7th dose level (6500 mg m À2 in 650 min) and one patient at 8th dose level. A total of 137 courses were administered and were evaluable for toxicity. In all, 15 courses were administered at 1st level, 19 at 2nd, 16 at 3rd, 15 at 4th, 32 at 5th, 27 at 6th, 13 at 7th and 1 at 8th. G3 -4 nonfebrile neutropenia occurred in 2.8% of courses, G3 anaemia in 6.5% of courses and G3 thrombocytopenia in 1.5% of courses. The patient treated at 7000 mg m À2 experienced a G4 mucositis and died 25 days after the first course of treatment.
Mucositis was considered the dose-limiting toxicity and 6500 mg m À2 was defined as the MTD. Other haematologic and nonhaematologic toxicities were mild or moderate: G2 fever was reported in 11.6% of courses, G1 dermatitis in 6.4% and G1 deep venous thrombosis in 2.9% (Table 2) .
Outcome
In all, 18 patients completed at least four courses of treatment and are evaluable for response. Four patients (22.2%) achieved an objective response: one patient achieved a complete remission lasting 21 þ months and three patients achieved a partial remission; seven patients (36.8%) had a stable disease. Seven patients experienced early progression. Five patients received less than four courses of chemotherapy due to refusal (two patients) and DVT (three patients). According to the intention-to-treat analysis, median time to progression was 4.8 months (95% CI 1.7 -7.9) and median OS was 7.0 months (95% CI 4.9 -9.1); the 1-year survival rate was 21.9%. (Figure 1 ).
Pharmacokinetic analysis
The plasma concentration of gemcitabine reached the target concentration of 15 mmol l À1 within 30 min from the start of infusion and remained above this threshold level during the infusion period. The maximum plasma concentration (C max ) of gemcitabine was achieved at the end of the infusion and ranged from 24.8473.93 to 84.36715.97 mmol l À1 , suggesting that there was heterogeneity in the plasma kinetics among the patients, whereas the AUC ranged from 5588.7271447.85 to 33402.9573136.62 min Â mmol l À1 , showing a dose-dependent increase. Gemcitabine rapidly disappeared from plasma, and 30 min after the end of drug infusion, only the metabolite dFdU was detectable. C max of dFdU ranged from 77.5178.70 to 144.431727.79 mmol l À1 and was achieved approximately 15 min after the end of gemcitabine infusion. The AUC ranged from 36 668.7673153.76 to 51 314.0878958.63 min Â mmol l À1 , corresponding to the 3000 -4500 mg m À2 dose levels; over the (Figure 4) . In contrast, no significant impact on OS was found both for dFdU AUC o40.000 min Â mmol l À1 and for dose level 44500 mg m À2 . Finally, among the other parameters studied, male sex was associated with shorter survival (median survival time, 5.22 months, 95% CI 1.75 -8.70, vs 10.02 months, 95% CI 3.20 -16.84, P ¼ 0.04), while no significant impact on OS was found for age (o56 years).
DISCUSSION
The MTD of gemcitabine is strongly associated to the infusion schedule: when administered daily for 5 days over 30 min, the MTD was reached at 9 mg m À2 day À1 (O'Rourke et al, 1994) ; on the other hand, when the drug was administered biweekly, the MTD was observed at 4000 mg m À2 day À1 (Brown et al, 1991) . In the pivotal trial conducted by Burris et al (1997) , gemcitabine produced a response rate of 5.4%, a median survival time of 5.7 months and the clinical benefit response in 23.8% of the patients. In this trial, gemcitabine was administered on a weekly basis as a 30-min infusion and this schedule has become the standard modality of administration. In a phase I trial, when gemcitabine was administered at FDR to patients with previously treated solid tumours including pancreatic cancer, the MTDs were 1500 mg m À2 over 150 min (Brand et al, 1997) and 1800 mg m À2 over 180 min weekly for 3 weeks (Touroutoglou et al, 1998) . Preclinical and clinical data suggest that an infusion rate of 10 mg m À2 min À1 may be more effective even if myelotoxicity can become the doselimiting toxicity (Veerman et al, 1996; Tempero et al, 2003 ). An FDR of 10 mg m À2 min À1 can provide plasma concentrations (approximately 20 mmol l À1 ) that are sufficient to maximise the rate of gemcitabine triphosphate accumulation. Two phase I trials have shown that a single course of gemcitabine as FDR infusion of 10 mg m À2 min À1 for 12 h can be safely administered alone or in combination with mitoxantrone in patients with relapsed/refractory acute leukaemia (Gandhi et al, 2002; Rizzieri et al, 2002) .
The data of our study demonstrate that multiple courses of gemcitabine can be administered at the FDR of 10 mg m À2 min
À1
up to 11 h every 14 days with peripheral blood stem cell support. Tolerability was excellent with a G4 neutropenia observed in 1.4% of the courses only, while other haematological and clinical toxicities were pgrade 3. All the courses were administered at the scheduled 2-week interval. Surprisingly, the first patient treated at the dose level of 7000 mg m À2 developed a severe mucositis and died at day 25 after the first course. It was therefore decided to stop the dose escalation in spite of excellent tolerability experienced by all other patients.
Unfortunately, the activity of this intensive treatment was lower than expected: an objective response was observed in 22.2% of patients, while a disease control (OR þ s.d.) was achieved in 61% of the patients; median TTP and OS were 4.8 and 7 months, Table 3 Plasma pharmacokinetics of gemcitabine and dFdU respectively, and 1 year survival rate was 21.9%. These results are inferior to those reported by Tempero et al (2003) with gemcitabine given at FDR of 1500 mg m À2 without peripheral blood stem cell support.
In agreement with Tempero et al, the mean plasma gemcitabine concentration at the end of an FDR infusion of 10 mg m À2 min . However, the FDR infusion was able to generate sustained gemcitabine levels in plasma above the threshold of 15 mmol l À1 , which is higher than the concentration required to achieve maximal intracellular accumulation of gemcitabine triphosphate; moreover, the gemcitabine AUC showed a dose-dependent increase. In contrast, the AUC of the gemcitabine metabolite showed a dose-dependent increase until the 4500 mg m À2 dose levels; above this dose level, the AUC did not increase, possibly depending on saturable metabolism.
The data of the present study also demonstrate a genotypephenotype correlation between CdA gene expression, enzyme activity and AUC of the metabolite dFdU produced by gemcitabine deamination by CdA. These findings are in agreement with a previous study by Schroeder et al that demonstrated a significant correlation between the amount of CdA mRNA and enzyme activity in leukaemic blasts, suggesting that variations in CdA activity depends on differences in gene expression. Schroder et al (1998) also showed a correlation of pretherapeutic CdA activity with induction treatment response with the nucleoside analogue cytarabine in patients with acute myeloid leukaemia. Kroep and co-workers have recently shown a clear correlation between dCK levels and gemcitabine sensitivity. In contrast to dCK, CDA activity was not clearly related to gemcitabine sensitivity (Kroep et al, 2002) .
In the present study, an univariate analysis demonstrated that patients whose mononuclear cells had higher CdA expression and activity levels had significantly higher rate of early progression and shorter OS than patients with lower CdA expression and activity levels, suggesting that gemcitabine metabolism in mononuclear cells could predict clinical outcome. The small number of patients in our study does not allow a multivariate analysis. Figure 4 Overall survival analysis according to CdA activity levels: À1 mg À1 (eight patients) and 42 nmol min À1 mg À1 (nine patients).
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